Loading...

NATCOPHARM Natco Pharma Ltd Changes in management or control Announcement

Ntc

NTCP

Natco Pharma Ltd

(NATCOPHARM)

2025 Announcement

Credit rating reaffirmation

FDA inspection outcome

Earnings Call Transcript

Unaudited results

Audio recording

Q2 FY26 Earnings Presentation

Interim Dividend

Dividend and Demerger

Interim Dividend

Crop Health Demerger

Equity stake acquisition

Q2FY26 Earnings Call

Board Meeting Notice

Everolimus Launch

Acquisition Update

Compliance Certificate

Management Change

Management Change

FDA Inspection Report

Acquisition Announcement

Investor Meeting

AGM Publication

New Product Launch

Earnings Call Update

Q1 Earnings Call

Financial Results Published

Q1 FY26 Earnings

Earnings Call Scheduled

New VP Appointment

Major Acquisition Announced

FDA Inspection Report

Investor Call Summary

Investor Presentation

Natco Acquisition Announcement

Management Changes

Newspaper Publication

Compliance Certificate

Management Changes

FDA Inspection Update

Management Change

FDA Inspection Results

Investor Meeting

Q4 FY25 Earnings

Volume Movement Clarification

Earnings Call Update

Financial Results Published

Earnings Presentation

Annual Compliance Report

Management Changes

Earnings Call Scheduled

Compliance Certificate

Risdiplam Legal Update

Management Change

Management Change

Management Change

Management Change

Investor Meeting

Tax Demand Order

Q3 FY25 Earnings

Earnings Call Audio

Newspaper Publication

Q3 FY25 Earnings

Director Resignation

Earnings Call Update

Bosentan Approval

Earnings Call Notice

Product Approval

GST Order Penalty

Compliance Certificate

Sustainability Report

Land Sale Announcement

Q2 Earnings Results

ANDA Submission

Investment Sale

Management Change

Dividend Announcement

Dividend Update

Earnings Call Recording

Dividend Announcement

Q2 FY25 Presentation

Management Change

Earnings Call Scheduled

Management Change

SEBI Compliance Certificate

Patent Settlement Update

Management Change

Investor Meeting

Investor Meeting

Investor Meeting

41st AGM Notice

NATCO Invests $8M

Investor Meet Notice

ANDA Submission

Investor Meeting

Q1 FY25 Earnings Update

Earnings Call Transcript

Interim Dividend Declared

Q1 FY25 Presentation

Management Changes

Investor Meeting

Delay in Resignation Submis...

Management Change

Investor Meeting

Management Change

earnings call transcript

ANDA Submission for Rimegep...

Investor Presentation

Financial Results Publication

Investor Presentation

Compliance Report Submission

Investor Meeting

Investor Meeting

USFDA Inspection

Investor Meeting

FDA Inspection Update

Compliance Certificate Subm...

Compliance Certification

Submission of PCS Certificate

Investor Meeting

Management Change

Newspaper Publications

Earnings Conference Call

Newspaper Publication

Q3 FY24 Investor Presentation

Restart of Factory Operations

Management Appointments

Acquisition of Eywa Pharma ...

Investment in Cellogen Ther...

Certificate Submission

Management Change

Dismissal from Lawsuit

Disruption of Operations

Investor Meeting

Earnings Conference Call

Uploaded audio recording

Investor Presentation

Resignation of Vice Preside...

Publication Advertisements

Earnings Report

Completion of Inspection

US FDA Inspection

Certificate submission

AGM Proceedings Announcement

Acquisition of ISCA, Inc.

Financial Statements

Financial Statements

Financial Statements

Audio Recording Uploaded

Financial Statements

Conference Call

External Links:

Data:

Dr. Ramesh Dandala has superannuated as Executive Vice President of Natco Pharma Ltd, effective April 3, 2025.

AI Assistant

Natco Pharma Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.